Gen-2 tACS device shows promising results in clinical study conducted by Nexalin Technology

In recent news, Mark White, CEO of Nexalin Technology, discussed the positive outcomes of a clinical trial involving their Gen-2 tACS device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI). The study took place at The University of California, San Diego in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System and various departments at UC San Diego.

The trial was a randomized, double-blind, placebo-controlled study lasting eight weeks. Two groups were involved: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve treatment sessions over four weeks, followed by a four-week observation period to analyze outcomes.

The encouraging results of this study are especially notable given the extensive market potential for therapies addressing traumatic brain injuries. The Traumatic Brain Injuries Assessment Market is forecasted to exceed $7.2 billion by 2032, according to Global Market Insights. Nexalin’s innovative approach shows promise in meeting the needs of individuals coping with mTBI, potentially enhancing their quality of life and offering hope for more effective treatment options in the future.

By Riley Johnson

As a content writer at, I dive into the depths of information to craft compelling stories that captivate and inform readers. With a keen eye for detail and a passion for storytelling, I strive to create engaging content that resonates with our audience. Whether it's breaking news, in-depth features, or thought-provoking opinion pieces, I am dedicated to delivering high-quality, informative content that keeps readers coming back for more. My goal is to bring a fresh perspective to every article I write and to make a meaningful impact through the power of words.

Leave a Reply